Literature DB >> 15476946

Cardiovascular role of urotensin II: effect of chronic infusion in the rat.

Andrew R Kompa1, Walter G Thomas, Fiona See, Alex Tzanidis, Ross D Hannan, Henry Krum.   

Abstract

Urotensin II (UII) is a potent vaso-active peptide thought to have multiple roles in the regulation of cardiovascular physiology and pathophysiology. The actions of UII are complex and difficult to interpret given its systemic hemodynamic effects and variable action on different vascular beds and isolated vessels. Direct effects of UII on the myocardium, include myocyte hypertrophy, extracellular matrix deposition and contractility. These observations, together with elevated plasma levels found in disease, are common traits reported in other pathophysiologically implicated neurohormonal systems. In this review, we include original data obtained from chronic infusion of UII in rats. We report a reduction in first derivative of left ventricular pressure (+dP/dt), as well as an increase in the ratio of left ventricular collagen I:III, that may contribute to the reduced myocardial contractility observed in these animals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15476946     DOI: 10.1016/j.peptides.2004.03.029

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  13 in total

1.  Urotensin-II in systemic sclerosis: a new peptide in pathogenesis.

Authors:  Yavuz Pehlivan; Ahmet Mesut Onat; Gazi Comez; Taner Babacan
Journal:  Clin Rheumatol       Date:  2011-01-28       Impact factor: 2.980

2.  Urotensin II alters vascular reactivity in animals subjected to volume overload.

Authors:  Gregory S Harris; Robert M Lust; Laxmansa C Katwa; Christopher J Wingard
Journal:  Peptides       Date:  2010-08-17       Impact factor: 3.750

3.  Urotensin-II induces ear flushing in rats.

Authors:  J-s Qi; R Schulingkamp; T J Parry; R Colburn; D Stone; B Haertlein; L K Minor; P Andrade-Gordon; B P Damiano
Journal:  Br J Pharmacol       Date:  2007-01-08       Impact factor: 8.739

Review 4.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

Review 5.  Urotensin-II and cardiovascular diseases.

Authors:  Nicolas Bousette; Adel Giaid
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

6.  Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.

Authors:  Stephen A Douglas; David J Behm; Nambi V Aiyar; Diane Naselsky; Jyoti Disa; David P Brooks; Eliot H Ohlstein; John G Gleason; Henry M Sarau; James J Foley; Peter T Buckley; Dulcie B Schmidt; William E Wixted; Katherine Widdowson; Graham Riley; Jian Jin; Timothy F Gallagher; Stanley J Schmidt; Lance Ridgers; Lisa T Christmann; Richard M Keenan; Steven D Knight; Dashyant Dhanak
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

7.  Effectiveness of palosuran in bleomycin-induced experimental scleroderma.

Authors:  Tuncer Demir; Ibrahim Turkbeyler; Davut Sinan Kaplan; Yavuz Pehlivan; Mustafa Orkmez; Ediz Tutar; Seyithan Taysi; Bunyamin Kisacik; Ahmet Mesut Onat; Cahit Bagcı
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

8.  PPAR-gamma expression in animals subjected to volume overload and chronic Urotensin II administration.

Authors:  Gregory S Harris; Robert M Lust; Jonathan H DeAntonio; Laxmansa C Katwa
Journal:  Peptides       Date:  2008-03-12       Impact factor: 3.750

9.  The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.

Authors:  David J Behm; Gerald Stankus; Christopher P A Doe; Robert N Willette; Henry M Sarau; James J Foley; Dulcie B Schmidt; Parvathi Nuthulaganti; James A Fornwald; Robert S Ames; David G Lambert; Girolamo Calo'; Valeria Camarda; Nambi V Aiyar; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

10.  Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula.

Authors:  Gregory S Harris; Robert M Lust; Laxmansa C Katwa
Journal:  Peptides       Date:  2007-05-06       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.